Samcheondang Pharmaceutical is accelerating the development of oral GLP-1 obesity and diabetes treatments and oral insulin, using its existing ophthalmic eye drop business as a foundation. However, as the company has been cited as a case that triggered recent reforms in the disclosure system for the pharmaceutical and biotech industry, transparency in disclosures and information delivery methods have emerged as key evaluation criteria among investors, on par with the new drug pipeline.

Founded in 1943, Samcheondang Pharmaceutical has steadily grown in the domestic eye drop manufacturing sector. The company established a stable business foundation centered on ophthalmic pharmaceuticals, such as dry eye treatments, and has been expanding its scope into biosimilars and oral drug platforms. According to Wikipedia, the company laid the groundwork for entering overseas markets by acquiring Optus Pharmaceutical in 2013 and obtaining EU GMP certification in 2015 and 2018.

Oral New Drug Pipeline as the Future Growth Axis

Current market attention is focused more on the new drug pipeline than on the existing ophthalmology business. The development of oral GLP-1 treatments and oral insulin is cited as a core focus.

According to a report by Newsis, Samcheondang Pharmaceutical's oral insulin (SCD0503) is currently undergoing global Phase 1 clinical trials at Profil, a German clinical research institution, and dosing has already been completed for one-third of the total patients. The company expects to complete Phase 1 trials in the fourth quarter of this year. However, this schedule is still in the clinical stage, and with further approval, additional clinical trials, and commercialization steps remaining, it is difficult to confirm actual sales or commercialization at this point.

The existing business also remains an important foundation. Samcheondang Pharmaceutical maintains a structure in which it invests in biosimilars and new platform development based on the stable cash flow from its ophthalmic eye drop business. With a strategy of pursuing both its existing prescription drug business and its future pipeline, the company is categorized as one that is simultaneously evaluated on short-term performance and long-term growth potential.

'Disclosure Reliability' Emerges as a New Evaluation Standard

Recently, disclosure practices have become a greater focus of market attention than research and development achievements. According to Comedy.com and Asia Economy, the Financial Supervisory Service has decided to comprehensively overhaul the disclosure system for pharmaceutical and biotech companies. Going forward, the push is toward requiring companies to separately disclose not only the total contract value but also the down payment, development milestones, licensing and sales milestones, and royalties when announcing technology transfer agreements.

Samcheondang Pharmaceutical's case is behind this change. The company was designated as an unfaithful disclosure entity by the Korea Exchange after it released overseas performance forecasts and technology transfer-related information in the form of press releases rather than official disclosures. Subsequently, the Financial Supervisory Service initiated efforts to improve the disclosure system to reduce instances where research and development information from pharmaceutical and biotech companies is conveyed differently in disclosures versus press reports.

This systemic change is significant in that it is not an issue limited to Samcheondang Pharmaceutical alone, but a standard applied across the entire industry. Going forward, the system is expected to shift toward specifically disclosing actual down payments, step-by-step milestones, expected timelines, and research and development history, rather than merely highlighting the overall scale of technology transfer agreements.

Three Checkpoints Investors Are Watching

In the market, there is a growing consensus to examine the following three factors when evaluating Samcheondang Pharmaceutical's future corporate value:

1. Clinical progress of core pipelines such as oral GLP-1 and oral insulin 2. Whether technology transfer agreements lead to actual down payments and milestones 3. The reliability of the company's disclosures in communicating with the market

Oral obesity drugs and oral insulin are fields with high growth expectations, but the information currently disclosed pertains to the development and clinical stages. The timing of actual commercialization and revenue recognition may vary depending on clinical results, approval procedures, and contract terms.

Ultimately, Samcheondang Pharmaceutical is evaluated as being in a situation where it must pursue its transformation from an ophthalmology-focused pharmaceutical company into an oral platform company while simultaneously addressing the challenge of restoring market confidence.

[※ This article summarizes the company's business and disclosure trends and does not recommend buying or selling any specific stock. Clinical trials and technology transfer agreements may vary depending on results and contract terms, and investment decisions and responsibilities lie with the investor. This article was written with AI assistance.]